Pediatric Oncology Branch
Pharmacology and Experimental
Therapeutics Section
Senior Investigator

National Cancer Institute
10 Center Drive
Building 10, Room 13C103
Bethesda, MD 20982

Phone: 301-496-7387
Fax: 301-480-8871
widemanb@mail.nih.gov

Dr. Widemann is a senior investigator at the NCI Pediatric Oncology Branch (POB). After obtaining her M.D., from the University of Cologne, Germany, in 1986, Dr. Widemann received board certification in pediatrics in 1992 and was a hematology/oncology fellow at NCI POB from 1992 to 1995. She subsequently joined the Pharmacology and Experimental Therapeutics Section of POB and received tenure at NCI in 2009. Dr. Widemann’s primary research interests are the development of targeted therapies for refractory childhood cancers and neurofibromatosis type 1-related tumors.

Dr. Widemann's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with pediatric cancers or neurofibroma/neurofibromatosis. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.

A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma NCI-12-C-0098, NCT01502410

A Phase I Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas NCI-12-C-0091, NCT01568632

Phase I Study of the Mitogen Activated Protein Kinase (MEK) 1 Inhibitor AZD6244 Hydrogen Sulfate in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) NCI-11-C-0161, NCT01362803

A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms NCI-11-C-0142, NCT01164163

A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia NCI-11-C-0141, NCT01231919

Phase II Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma NCI-11-C-0115, NCT01207687

Phase I Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors NCI-11-C-0053, NCT01141244

Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors NCI-11-C-0047, NCT01259479

A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma NCI-10-C-0178, NCT01182896

A Phase II Trial of Peginterferon Alpha-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic, or Life-Threatening Plexiform Neurofibromas NCI-08-C-0130, NCT00678951

Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis NCI-08-C-0079, NCT00924196

Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Cancer NCI-07-C-0189, NCT00514046

A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib) in Children With Refractory Solid Tumors or Refractory Leukemias NCI-06-C-0233, NCT00343694

Phase II Trial of Neoadjuvant Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors NCI-06-C-0043, NCT00304083